title: Performance of the DiaSorin LIAISON(®) anti-HBs II for the detection of hepatitis B surface antibodies: comparison with the Abbott Architect anti-HBs assay.
abstract: BACKGROUND
  Detection of hepatitis B virus (HBV) surface antibodies (anti-HBs) is required in order to evaluate the response to hepatitis B vaccination and to optimize post-exposure monitoring. The widespread use of vaccines has highlighted the need for accurate and consistent quantification, yielding comparable quantitative results.
  
  
  OBJECTIVE
  This study assessed the adequacy of DiaSorin LIAISON(®) anti-HBs II assay in detecting anti-HBs antibodies and determined the correlation with Abbott Architect anti-HBs quantification.
  
  
  METHODS
  Anti-HBs levels were measured in parallel using Abbott and DiaSorin kits on WHO international standard dilutions and 350 routine samples pre-screened with Abbott Architect anti-HBs. Three different serological panels were tested: vaccinated subjects (n=121); subjects with past HBV infection (n=109); and subjects with no HBV infection marker (n=69). Serial dilutions from nine high-titer anti-HBs samples were used to address linearity.
  
  
  RESULTS
  Anti-HBs concentration measured on WHO standard dilutions indicated a good calibration of DiaSorin values against international units, while results for Abbott were below those expected. A strong impact of the dilution matrix used was observed when performing dilutions on high-titer samples. Despite difference in absolute quantification, the overall clinical agreement between the two assays was 96.9%, with strong correlation (r=0.92) between concentrations and good linearity over the quantification range.
  
  
  CONCLUSIONS
  The DiaSorin LIAISON(®) anti-HBs II assay shows excellent standardization to the WHO standard and good linearity. The assay is suitable for current clinical laboratory practice.
authors.affiliation: Virology Laboratory, Hôpital Pitié-Salpêtrière, Assistance Publique (APHP), and ER 1 Pierre et Marie Curie University, Paris 6, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Kinn
authors.forename: Sepideh
authors.initials: S
authors.lastname: Akhavan
authors.forename: Henri
authors.initials: H
authors.lastname: Agut
authors.forename: Vincent
authors.initials: V
authors.lastname: Thibault
mesh_terms: D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood* / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012698:Serologic Tests / Q000379:methods*
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011933:Reagent Kits, Diagnostic